Side-by-side evidence map
| Question | Retatrutide | Tirzepatide |
|---|---|---|
| Mechanism | GLP-1, GIP, and glucagon agonism | GIP and GLP-1 agonism |
| Regulatory status | Investigational | FDA-approved for specific indications |
| Core evidence | Phase 2 peer-reviewed; Phase 3 program active | Large phase 3 programs and approved labeling |
| Direct comparison | No head-to-head trial | No head-to-head trial |
How to read the numbers
A larger percentage reported in one trial does not prove superiority over a result from another trial. A valid treatment comparison requires a head-to-head design or a carefully specified indirect analysis.
What this evidence review covers
Compare triple versus dual agonism, status, and separate obesity trials without cross-trial ranking.
- Receptor and regulatory comparison
- Retatrutide phase 2 context
- SURMOUNT-1 phase 3 context
- Adverse-event comparison by source, not pooled
- No switching/stacking guidance
Source-backed findings
Each claim below is tied to the evidence class that can support it. Commercial listing data and clinical evidence remain separate.
mechanism and status
The molecules differ in receptor targets and regulatory status.
cross-trial limitation
Retatrutide and tirzepatide weight outcomes come from different randomized trials and cannot establish direct superiority.
| Evidence class | What the source supports |
|---|---|
| mechanism and status | The molecules differ in receptor targets and regulatory status. |
| cross-trial limitation | Retatrutide and tirzepatide weight outcomes come from different randomized trials and cannot establish direct superiority. |
Source-by-source evidence notes
These notes state what each inspected source can support and the boundary that should not be crossed when interpreting it.
Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial
Evidence class: primary randomized phase 2. What it supports: n=338 obesity/overweight trial; receptor description; dose arms; 24- and 48-week weight outcomes; reported adverse events.
What it does not establish: Approved use, long-term benefit-risk, vendor-product equivalence, cross-trial superiority, or a consumer protocol.
SURMOUNT-1 tirzepatide obesity trial
Evidence class: primary randomized phase 3. What it supports: n=2,539; 72-week weight outcomes and gastrointestinal adverse events in adults without diabetes.
What it does not establish: A head-to-head comparison with retatrutide or evidence about unapproved research material.
FDA concerns with unapproved GLP-1 drugs used for weight loss
Evidence class: primary regulatory. What it supports: Retatrutide and cagrilintide are not components of approved drugs, have not been found safe and effective, and cannot be used in compounding under federal law; FDA warnings about false research labels.
What it does not establish: A general claim that every observed listing is unlawful in every jurisdiction.
Questions this page answers
Is Retatrutide stronger than tirzepatide?
That conclusion is not supported by these separate trials; use a side-by-side design/population table instead.
Can someone switch or combine them?
This page does not provide switching, washout, stacking, or dose guidance.
What remains unresolved
- No direct head-to-head trial.
- No supported switching or combination protocol.
- Approved tirzepatide labeling should be refreshed at publication.